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1  | INTRODUC TION
Cutaneous melanoma makes up approximately 4% of skin cancers, 
yet it is responsible for more than 70% of skin cancer‐related deaths 
(Sample & He, 2018). Somatic melanoma genetics are complex with 
tumors exhibiting high mutational load mostly attributed to UV‐
induced DNA damage (Hodis et al., 2012). New germline genetic 
variants and genes contributing to melanoma susceptibility and 
progression are continually being discovered (Amos et al., 2011; 
Barrett et al., 2011; Bishop et al., 2009). Recently, genome‐wide asso‐
ciation studies (GWAS) have linked rs45430 SNP, a major T to minor 
C allele change, intronic to MX2 (myxovirus resistance 2) gene with 
reduced risk to cutaneous melanoma, and multiple primary tumors 
(Barrett et al., 2011; Gibbs et al., 2015). However, the functional role 
of this SNP or MX2 gene itself in the tumorigenesis has so far not 
been elucidated. MX2 protein is a dynamin‐like GTPase2 identified 
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Abstract
MX2 protein is a dynamin‐like GTPase2 that has recently been identified as an in‐
terferon‐induced	restriction	factor	of	HIV‐1	and	other	primate	lentiviruses.	A	single	
nucleotide polymorphism (SNP), rs45430, in an intron of the MX2 gene, was previ‐
ously reported as a novel melanoma susceptibility locus in genome‐wide association 
studies. Functionally, however, it is still unclear whether and how MX2 contributes 
to melanoma susceptibility and tumorigenesis. Here, we show that MX2 is differen‐
tially expressed in melanoma tumors and cell lines, with most metastatic cell lines 
showing lower MX2 expression than primary melanoma cell lines and melanocytes. 
Furthermore, high expression of MX2 RNA in primary melanoma tumors is associated 
with	 better	 patient	 survival.	Overexpression	 of	MX2 reduces in vivo proliferation 
partially through inhibition of AKT activation, suggesting that it can act as a tumor 
suppressor in melanoma. However, we have also identified a subset of melanoma cell 
lines with high endogenous MX2 expression where downregulation of MX2 leads 
to	 reduced	proliferation.	 In	 these	cells,	MX2 downregulation interfered with DNA 
replication and cell cycle processes. Collectively, our data for the first time show that 
MX2 is functionally involved in the regulation of melanoma proliferation but that its 
function is context‐dependent.
K E Y W O R D S
cell	cycle,	melanoma‐specific	survival,	MX2,	PI3K/AKT,	SNP
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as	an	interferon	(IFN)‐induced	restriction	factor	for	several	primate	
lentiviruses	including	HIV‐1	(Buffone,	Schulte,	Opp,	&	Diaz‐Griffero,	
2015; Goujon et al., 2013). Humans possess two MX genes, MX1 and 
MX2, with a high level of homology (Haller, Staeheli, Schwemmle, & 
Kochs,	2015).	While	MX1	protein	is	mainly	induced	after	type	I	IFN	
(IFNα/β) stimulation during the antiviral response (Haller & Kochs, 
2010; Kim, Shenoy, Kumar, Bradfield, & MacMicking, 2012), MX2 
can	 be	 expressed	 at	 significant	 levels	 even	 in	 the	 absence	 of	 IFN	
(King, Raposo, & Lemmon, 2004). Unlike MX1, MX2 has an extended 
N‐terminal domain and exists as two isoforms. While the longer 
78 kDa isoform displays antiviral activity and is associated with the 
nuclear envelope, the shorter 76 kDa isoform is cytoplasmic with‐
out clearly defined cellular activity to date (Haller et al., 2015). MX2 
found in association with nuclear pores contributes to the regulation 
of viral DNA nuclear import and/or integration into the host cell ge‐
nome	(Kane	et	al.,	2013).	One	previous	study	suggested	that	MX2	
could have additional, viral‐independent cellular functions including 
regulation of cell cycle progression (King et al., 2004).
Here, we show for the first time, to best of our knowledge, that 
MX2 is functionally involved in cancer‐related processes in mela‐
noma.	It	is	differentially	expressed	in	melanoma	tumors	and	cell	lines,	
and	it	is	a	predictor	of	better	patient	survival.	Interestingly,	our	data	
further show that MX2 function is complex, with both tumor‐sup‐
pressive and oncogenic features depending on the cellular context.
2  | MATERIAL S AND METHODS
2.1 | Cell lines and culture conditions
Primary human melanocytes (NHM9, NHM134, and NHM160) were 
isolated and cultured as previously described (Magnussen et al., 2012). 
Metastatic melanoma cell lines (MM) were established from melanoma 
patients	treated	at	the	Norwegian	Radium	Hospital,	Oslo	University	
Hospital as described in Flørenes et al., (2019). Melanoma cells 
were	cultured	in	RPMI	1,640	medium	(BioWhittaker)	supplemented	
with 5% fetal bovine serum (FBS, Sigma) and 2 mM/L L‐glutamine 
(GibcoBRL)	and	maintained	at	37°C	in	a	humidified	5%	CO2	atmos‐
phere. Primary melanocytes were grown in 254CF melanocyte media 
purchased from Gibco Life Technologies supplemented with calcium 
chloride, HMGS‐2 (human melanocytes growth supplement‐2), and 
10 ng/ml PMA. HEK293T cells (Clontech) were maintained in 4.5 g/L 
glucose, 4 mM L‐glutamine Dulbecco's modified Eagle's medium (cat. 
no	BE12‐604F/U1;	Lonza	BioWhittaker)	supplemented	with	10%	FBS,	
and 25 mM HEPES (cat. no H0877, Sigma‐Aldrich).
2.2 | siRNA knockdown
Described	in	the	Supporting	Information	Data	S1.
2.3 | Double thymidine block
Cells	were	 synchronized	 at	 G1/S	 using	 a	 double	 thymidine	 block.	
At approximately 30% confluency, MM382 cells were subjected to 
culturing media supplemented with 2 mM thymidine for 16 hr (first 
block). Afterward, thymidine was washed off twice with PBS and 
cells were allowed to grow for 8 hr in normal conditions. Thymidine 
at final concentration of 2 mM was added for additional 15 hr before 
final release. Cells were collected at 0‐, 2‐, 4‐, 6‐, 8‐, 10‐, and 12‐hr 
time points after release.
2.4 | Cell viability
Two x 105 cells per well were seeded into 6‐well plates 24 hr be‐
fore	treatment	with	siRNA.	Cells	were	trypsinized	and	collected,	
and the total number was counted after 72 hr of treatment with 
siRNA. Viability values are presented as a mean percentage ± SE 
of	three	independent	experiments	normalized	to	the	negative	con‐
trol siRNA.
2.5 | RNA sequencing and analysis
The RNA‐seq files (fastq) prior to analysis were treated with 
Trimmomatic‐0.38 (Bolger, Lohse, & Usadel, 2014) to remove se‐
quence adapters. After trimming, the reads were (quasi)‐mapped 
directly to the transcriptome using human (GRCh38, Ensemble ver‐
sion	94),	Salmon	software	(Patro,	Duggal,	Love,	Irizarry,	&	Kingsford,	
2017). The DESeqDataSet was constructed by importing transcript 
abundance estimates from Salmon using the R txtimport package 
(Soneson et al., 2015), differentially expressed genes detected by R 
DESeq2 package (Love, Huber, & Anders, 2014). For the selection of 
differently expressed genes, a significance threshold based on ad‐
justed p‐value <.01 was applied. To further strengthen the selection, 
significantly (p < .01) expressed genes from three groups, combined 
(knockout 1 and knockout 2) and individually, were compared. From 
these, a core of 520 genes was selected based on overlapping ex‐
pression between the groups.
2.6 | Data
Sequence data are stored at Services for Sensitive Data (TSD)—
University	of	Oslo.	Access	can	be	arranged	by	contacting	 the	cor‐
responding author (Ana S.) upon request. Graphical presenstations: 
Heatmaps were constructed using aheapmap function in R package 
Significance
The study provides the first evidence that antiviral MX2 
gene is associated with the tumorigenesis process in mela‐
noma.	It	has	an	IFN	independent	role	in	the	regulation	of	cell	
cycle	and	the	PI3K/AKT	pathway.	However,	MX2	function	
is	clearly	cell	type‐	and	context‐dependent.	Our	findings	are	
adding a functional explanation to previous genome‐wide 
association studies that reported an association between 
MX2 gene and reduced risk for melanoma.
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NMF	 (Gaujoux	&	Seoighe,	 2010).	 The	 enrichGO	 function	 in	 the	R	
package Clusterprofiler (Yu, Wang, Han, & He, 2012) was used for 
the	GO	over‐representation	plots.
2.7 | Incucyte growth rate assessment
Cells overexpressing MX2 and GFP as a control were seeded into 
24‐well plate at a density of 25,000 cells per well. Cell proliferation 
was	measured	by	a	confluence	assay	using	 IncuCyteTM FLR (Essen 
Instruments)	 live‐cell	 imaging	system.	Phase‐contrast	 images	were	
generated every 3 hr over a period of 3 days (for melanoma cells) 
or 4 days (for melanocytes). Cell proliferation was determined by 
analyzing	cell	confluence	over	 time.	The	experiment	was	repeated	
three	 times	 in	 triplicate.	Confluence	values	were	normalized	 to	an	
initial time point; data are presented as a mean value at a given time 
point ± SE.
2.8 | Cytoplasmic and nuclear fractionation
NE‐PER Nuclear and Cytoplasmic Extraction Reagent kit (cat. no. 
78833; Thermo Fisher Scientific) was used to isolate cytoplasmic 
and	nuclear	proteins.	Isolation	was	performed	according	to	the	man‐
ufacturer's	 instructions.	 Halt	 Protease	 Inhibitor	 Cocktail	 (cat.	 no.	
87785;	Thermo	Fisher	Scientific)	was	added	to	the	CER	I	and	NER	
extraction reagents before use.
2.9 | Flow cytometric analysis
For cell cycle analysis, 2 × 105 cells per well were seeded into 6‐well 
plates 24 hr before treatment with siRNA. Forty‐eight hours after 
transfection,	cells	were	harvested	by	 trypsinization,	washed	 twice	
in ice‐cold PBS, and fixed resuspending cell pellets in 1 ml 70% ice‐
cold methanol. Fixated cells were stained with a ready‐to‐use DNA 
Labelling	Solution	(Cytognos,	cat.	no.	CYT‐PIR‐25).	Flow	cytometric	
experiments were performed on BD FACSCaliburTM Flow cytometer 
(BD	Biosciences).	Data	were	analyzed	with	FlowJo	v.7.6.1	software	
(Treestar	Inc.	Ashland).
2.10 | Quantitative real‐time PCR
Described	in	the	Supporting	Information	Data	S1.
2.11 | Rs45430 SNP genotyping
qPCRs were performed in duplicate in 96‐well plates. Five nano‐
gram of genomic DNA (gDNA) was mixed with TaqMan Genotyping 
Master Mix (cat. no 4371353; Applied Biosystems) and TaqMan 
SNP	Genotyping	Assay	(cat.	no	4351379,	assay	ID	C_2564407_10;	
Applied Biosystems) specific for rs45430 polymorphism. PCRs 
were performed on a QuantStudioTM5 Real‐Time PCR system 
(Applied Biosystems, Thermo Fisher Scientific) running the fol‐
lowing	program:	 (a)	enzyme	activation	at	95ºC	for	10	min,	 (b)	40	
cycles	of	PCR	at	95ºC	for	15	s,	and	60ºC	for	1	min.	Genotypes	of	
the samples were determined from the allelic discrimination and 
amplification plots.
2.12 | Generation of MX2 and GFP 
expression constructs
MX2	 cDNA	was	 purchased	 from	OriGene,	 catalog	 no.	 SC127459.	
Entry vector encoding GFP—pENTRY‐GFP—was a gift from William 
Hahn (Addgene plasmid #15301). A destination vector pLenti‐
CMV‐Puro‐DEST (w118‐1) was a gift from Eric Campeau and Paul 
Kaufman; Addgene plasmid #17452. pCW57.1 construct was a gift 
from David Root; Addgene plasmid #41393. Detailed procedures for 
plasmid	 construction	 are	 described	 in	 the	 Supporting	 Information	
Data S1.
2.13 | Lentivirus production and generation of 
stable cell lines
Described	in	the	Supporting	Information	Data	S1.
2.14 | In vivo animal studies
WM983b cells (2 × 106) stably expressing MX2 or GFP diluted in 
200	µl	serum‐free	RPMI‐1640	media	were	subcutaneously	injected	
in	the	right	flank	of	nude	mice	(athymic	nude	foxn1	nu).	Tumor	sizes	
were measured once a week using a caliper, and the volume V was 
calculated as follows: V = W2 × L × 0.5 (where W and L are tumor 
width and length, respectively). The experimental protocol was 
evaluated and approved by the National Animal Research Authority 
and conducted in accordance with regulations of the European 
Laboratory Animals Science Association.
2.15 | Immunoblotting
Immunoblotting	was	performed	as	previously	described	(Magnussen	
et al., 2012) with few modifications. Cells were lysed with ice‐
cold NP‐40 lysis buffer supplemented with phosphatase in‐
hibitor (4906837001, Roche Diagnostics) and protease inhibitor 
(4693124001, Roche Diagnostics). Proteins were resolved on 4%–
20% or 10% gels (Bio‐Rad) by SDS‐PAGE electrophoresis. List of an‐
tibodies	used	is	presented	in	Table	S1.	Visualization	was	performed	
with SuperSignal West Dura Chemiluminescence kit (Pierce).
2.16 | Clinical melanoma specimens for IHC
Formalin‐fixed, paraffin‐embedded tissue from 42 benign nevi, 154 
primary melanomas, and 60 metastases was examined for expression 
of MX2 protein. Clinical follow‐up was available for all patients, 72 
male and 82 female, with the mean age of 55.6 (range 19–97). The fol‐
low‐up period ranged from 1 to 361 months (mean = 104.8 months, 
median = 126.5 months). The Regional Committee for Medical 
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Research Ethics South of Norway (S‐06151) and The Social and 
Health Directorate (06/2733) approved the current study protocol.
2.17 | Immunohistochemical analysis
Immunohistochemical	 staining	 procedure	 is	 described	 in	 the	
Supporting	 Information	 Data	 S1.	 Semiquantitative	 classification	
was used to describe staining intensity (absent = 0; weak = 1; 
moderate = 2; strong = 3) and percentage of positive tumor cell 
(absent = 0; 0%–25% = 1; 25%–50% = 2; 50%–75% = 3; >75% = 4). 
By multiplying intensity score with percentage positive cell score, 
a total immunoreactivity score was calculated ranging from 0 
to	12.	 Immunoscore	>3	was	considered	as	high	 in	 the	statistical	
analyses.
2.18 | Mitotic rate classification
Mitotic rate was histologically assessed by count of mitoses per 
mm2,	also	described	in	Poźniak	et	al.,	(2019).
2.19 | Statistical analysis
Statistical analysis was performed applying SPSS package version 
18,	 (SPSS	 Inc.)	and	Stata	14.2.	Comparison	between	variables	was	
performed using the chi‐square test or Fisher exact test. Two‐tailed 
paired Student's t test and Wilcoxon matched‐pairs signed‐rank test 
was used for the evaluation of in vitro results. A p value of less than 
.05	was	considered	statistically	significant.	In	the	Leeds	Melanoma	
Cohort (LMC) (Nsengimana et al., 2018), the relationship between 
MX2 expression and mean tumor thickness was evaluated using 
Mann–Whitney two‐sample test. Melanoma‐specific survival (MSS) 
analysis of MX2 gene expression was performed using univariate 
Cox	proportional	hazard	model	in	the	whole	dataset,	and	in	each	of	
the immune subgroups (low, intermediate, and high). The generation 
of	 the	 immune	 subgroups	was	 defined	 in	 Poźniak	 et	 al.,	 (2019)	 in	
which immune cell infiltration was imputed using the expression of 
genes reported to be exclusively expressed by each immune cell. The 
Kaplan–Meier	 curve	 was	 generated	 after	 dichotomizing	 MX2 ex‐
pression by median (high and low). The difference of MX2 expression 
was tested among the three immune subgroups using Kruskal–Wallis 
and Dunnett's test. Kaplan–Meier survival estimates and log‐rank 
tests were used to evaluate the survival data.
2.20 | Transcriptomic data
Generation of gene expression data from 703 FFPE tumors of the 
LMC was as described elsewhere (Nsengimana et al., 2018). These 
data were deposited in the European Genome‐phenome Archive 
(EGA), accession number EGAS00001002922. Gene expression 
from metastatic melanomas in The Cancer Genome Atlas (TCGA) 
was downloaded from c‐bioportal (http://www.cbiop ortal.org/) and 
was classified into the three immune subgroups as reported previ‐
ously	(Poźniak	et	al.,	2019).
3  | RESULTS
3.1 | MX2 is constitutively and differentially 
expressed in melanoma tumors and cell lines
To investigate the potential role of MX2 in melanoma, we first exam‐
ined its RNA and protein expression in a panel of human melanocytes, 
established	primary	and	metastatic	melanoma	cell	lines.	Immunoblot	
analysis revealed constitutive, yet differential MX2 protein expression 
that correlated with RNA levels (Figure 1a,b). Most metastatic lines 
expressed lower levels of MX2 compared to the primary melanoma 
and cultured melanocyte lines. Furthermore, an apparent reduction 
of MX2 protein level was seen in metastatic WM239 line compared 
to primary WM115 line, both derived from the same patient, suggest‐
ing that MX2 is downregulated during disease progression.
Interestingly,	the	highest	MX2	protein	expression	was	seen	in	the	
recently established early passage metastatic MM382 line. To rule 
out that this could be an in vitro culturing artifact, we also examined 
MX2 expression in the original tumor sample that was histologically 
dissected and evaluated to contain more than 80% of tumor cells, 
and found it to be comparable to the cell line (Figure 1c,d). Variable 
expression of MX2 RNA was also observed in 45 fresh metastatic 
melanoma tumor samples, derived from lymph nodes. The majority 
(31/45)	of	samples	had	lower	relative	RNA	levels	when	normalized	
to primary WM1366 cell line (Figure 1e). Furthermore, there was 
no statistically significant difference in MX2 expression between 
BRAFV600E mutant and wild‐type samples (Table S2).
We also investigated whether rs45430 SNP is associated with 
MX2 expression in both cell lines and metastatic melanoma samples 
(Figure 1a,e). While we observed a tendency for TT genotype to 
be associated with a higher MX2 expression, it was not statistically 
significant.
In	other	cell	 types,	MX2 expression is shown to be induced by 
IFN	signaling.	To	examine	whether	this	is	valid	in	melanoma,	we	in‐
cubated the low and high MX2 expressing cell lines WM983b and 
MM382	with	IFNα	or	IFNγ	for	24h.	IFNα/γ treatment resulted in up‐
regulation of both RNA and protein MX2 level (Figure 1f and Figure 
S1a), confirming that MX2	 is	 an	 IFN	 response	 gene	 in	melanoma,	
though	it	can	also	be	constitutively	expressed	independently	of	INF	
stimulation.
We also examined possible association between MX2 expression 
and related MX1, in the same cell lines and tumor samples. We ob‐
served no correlation between MX2 and MX1 protein (Figure S1b) 
and mRNA expression (Figure S1c,d) in the cell lines. However, in 
tumor samples MX2 and MX1 mRNA expression significantly cor‐
related, possibly due to the contribution of microenvironment‐de‐
rived	IFN	(Figure	S1e,f).
Antiviral functions of MX2 have been associated with its lo‐
calization	 to	 the	 nuclear	 envelope;	 however,	 cytoplasmic	 localiza‐
tion has also been reported (Dicks et al., 2018; Melén et al., 1996). 
Cytoplasmic and nuclear fractionation of melanoma cell lines showed 
that MX2 protein is mainly found in the nuclear fraction, but a weak 
cytoplasmic	localization	was	also	detected	(Figure	1g).
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3.2 | MX2 expression is associated with longer 
melanoma‐specific survival
Using previously described whole transcriptome data derived from 
703 primary melanomas from the Leeds Melanoma Cohort (LMC) 
(Nsengimana et al., 2018), we investigated the expression and asso‐
ciation of MX2 mRNA level with melanoma‐specific survival (MSS). 
A	Kaplan–Meier	curve	was	generated	after	dichotomization	of	MX2 
expression to high and low groups with respect to the median show‐
ing that higher MX2 expression was associated with longer mela‐
noma‐specific survival (HR = 0.8, p = .004) (Figure 2a). Similar results 
were observed in the TCGA melanoma metastases—application of 
Cox	proportional	hazards	model	after	median‐based	dichotomiza‐
tion revealed that high MX2 expression was associated with better 
overall patient survival (N = 339, HR = 0.7, p = .026) (Figure 2b).
Furthermore, weak yet significant negative correlation was ob‐
served between MX2 expression and Breslow thickness (R	=	−0.2,	
p = 5.4 × 10–8) as well as MX2 and the mitotic rate (R	 =	 −0.13,	
p = .002) in the LMC (Figure S2a and b).
Since interferon signaling, which might induce MX2, is involved 
in	immune	cell	infiltration	in	tumors,	we	analyzed	MX2 expression in 
the LMC stratified by strength of immune signal resulting in three 
immune subgroups. The generation of the immune subgroups was 
defined	 in	Poźniak	et	al.,	 (2019).	MX2 expression was significantly 
lowest in the low immune and highest in the high immune subgroup 
(Figure 2c). Comparable results were seen in the TCGA melanoma 
metastases cohort (Figure S2c).
The analysis of LMC also showed associations between MX2 
expression and histologically detected tumor‐infiltrating lympho‐
cytes	(TILs)	(Figure	S2d).	MX2 expression was significantly higher in 
tumors	with	TILs	in	comparison	with	tumors	that	had	no	TILs.	We	
then compared the association between MX2 expression and MSS 
in the LMC primary tumors stratified by strength of immune sig‐
nal. MX2 expression was borderline protective in the low immune 
subgroup. The results for the intermediate and high immune sub‐
groups	were	not	significant	but	show	similar	estimates	of	the	haz‐
ard ratio so their lack of significance may simply reflect relatively 
small	sample	size	(Table	1).	There	was	no	association	between	MX2 
F I G U R E  1  Characterization	of	MX2	expression.	(a)	The	analysis	of	MX2	protein	expression	by	immunoblotting	(β‐actin used as a loading 
control). BRAF V600E and rs45430 status specified under the cell names: ND—not determined, WT—wild type, +—mutation is present. (b) 
MX2 mRNA expression in normal human melanocytes (NHM), and primary and metastatic melanoma lines (mRNA expression is presented 
as a mean value ± SE of three independent experiments). MX2	mRNA	expression	is	normalized	to	primary	melanoma	WM1366	cell	line.	
(c) Comparison of MX2 protein expression in established melanoma WM382 line and original tumor sample by immunoblotting and (d) 
immunohistochemistry. (e) MX2 mRNA expression in metastatic melanoma tumor samples. Tumors expressing lower MX2 mRNA levels 
compared	to	primary	WM1366	are	inside	the	dashed	rectangle.	Columns	are	colored	according	to	rs45430	genotype.	(f)	Increase	of	MX2 
mRNA	and	protein	expression	after	treatment	with	IFNα	1,000	IU/ml	for	24	hr	(mRNA	expression	is	presented	as	a	mean	value	±	SE	of	
three independent experiments). (g) Cytoplasmic and nuclear expression of MX2 in normal human melanocytes, and primary and metastatic 
melanoma	cell	lines	examined	by	immunoblotting.	Each	MX2	blot	was	visualized	separately
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expression and MSS in the TCGA stratified by immune status (data 
not shown).
We also tested whether rs45430 SNP is associated with MX2 
expression in the primary melanomas. The SNP data were generated 
as previously described (Law et al., 2015). The expression of MX2 
was	significantly	lower	in	participants	homozygous	for	the	C	allele	in	
comparison with the CT or TT genotype (Figure 2d).
Protein	 expression	 of	 MX2	 was	 also	 analyzed	 by	 immunohis‐
tochemistry in a second melanoma dataset consisting of 42 par‐
affin‐embedded nevi, 154 primary melanomas, and 60 metastatic 
melanomas. As shown in Figure 2e, cytoplasmic and/or nuclear 
expression was observed. Note that a variable MX2 staining was 
also observed in infiltrating immune cells.
Comparably high MX2 expression (immunoscore >3) was seen 
in nevi (21.4%), primaries (26.6%), and metastases (24%). However, 
complete lack of immunoreactivity was observed in 2.4% nevi, 7.8% 
primary, and 15% metastatic tumors, respectively, suggesting that 
MX2 is downregulated during disease progression in a proportion 
of tumors. The analysis of disease‐specific and progression‐free 
survival in this cohort showed no significant correlation with MX2 
expression. There was a significant positive correlation observed be‐
tween MX2 expression and extent of tumor‐infiltrating immune cells 
in the tumors (R = 0.23, p = .008).
3.3 | Overexpression of MX2 reduces melanoma 
proliferation by reducing activation of the PI3K/
AKT pathway
To further investigate the functional role of MX2 in melanoma, we 
stably overexpressed MX2 in normal human melanocytes NHM134, 
NRAS mutant WM1366, and BRAF mutant metastatic WM983b cell 
line. To develop a stable melanocyte cell line expressing MX2 or 
F I G U R E  2   Expression of MX2 is 
associated with a better melanoma‐
specific survival. (a) Kaplan–Meier 
melanoma‐specific survival analysis of 
703 primary melanomas and (b) Kaplan–
Meier overall survival analysis of 339 
TCGA metastatic melanomas stratified 
by median MX2 RNA expression where 
low is defined as bellow median. The 
analysis performed applying univariate 
Cox	proportional	hazard	model.	(c)	MX2 
RNA expression in high, intermediate, and 
low immune subgroups. (d) Expression 
quantitative trait loci (eQTL) analysis of 
MX2 gene single nucleotide polymorphism 
rs45430 in 703 primary melanomas (e) 
Representative immunohistochemistry 
staining of MX2 in (1) nevi, (2) primary, 
and (3 and 4) metastatic melanoma
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GFP,	we	used	the	Tet‐On	doxycycline‐inducible	system.	As	shown	
in Figure 3a, a clear increase in MX2 protein levels was observed 
in all cell lines after selection or induction when compared to GFP 
expressing	 control	 vector‐transfected	 cells.	 In	 vitro	 effects	 of	 in‐
creased MX2 protein levels on proliferation were assessed using 
IncuCyte™	analyzing	the	area	occupied	by	the	cells	(%	confluence).	
The relative confluence of cells growing under normal conditions for 
72 hr was significantly reduced in MX2 overexpressing WM1366 
and WM983b cells compared to their respective GFP controls 
(Figure 3b). This inhibitory growth effect was not observed in nor‐
mal melanocytes. No visibly detectable phenotypical changes were 
observed in the engineered melanocytes overexpressing GFP and 
MX2 (Supporting Figure S3a). Furthermore, we found no effects 
on expression of melanocyte differentiation markers Melan‐A and 
MITF	(Figure	S3b).
To study whether the effect of MX2 overexpression was relevant 
for tumor formation in vivo, WM983b and WM1366 cells overex‐
pressing MX2 or control protein GFP were subcutaneously injected 
into the right flank of athymic nude mice. As shown in Figure 3 pan‐
els c and d, overexpression of MX2 significantly suppressed tumor 
growth compared to GFP control group of WM983b cells. WM1366 
MX2 and GFP expressing cells displayed poor in vivo growth proper‐
ties, and no tumor growth was detected for up to 50 days.
In	 an	 attempt	 to	 explain	 the	 observed	MX2	 growth	 inhibitory	
effects,	 we	 analyzed	 known	 survival	 and	 proliferation	 signaling	
pathways including the MAPK and AKT pathways in extracted 
tumor xenograft lysates. We found that overexpression of MX2 
led to reduced phosphorylation of AKT regulatory residues Thr308 
and Ser473, decreased levels of AKT downstream phosphoprotein 
GSK3β, and a minor increase in PTEN protein levels, suggesting that 
the activity of the pathway is reduced. Furthermore, we observed el‐
evated expression levels of Wee1 and the tumor suppressor p21Cip1 
(Figure 3e) suggesting abrogation of the cell cycle. We did not ob‐
serve significant changes to the MAPK pathway. The same results 
were obtained in vitro for both WM1366 and WM983b cells (Figure 
S3c) suggesting that MX2 contributes to the regulation of the cell 
cycle and proliferation, displaying tumor suppressor features.
3.4 | MX2 function in melanoma is cell line‐
dependent
Since we observed that a subset of melanoma cell lines displays 
high constitutive MX2 expression, it is possible that these cells have 
adapted to circumvent its growth inhibitory effects or that MX2 has 
a different functional role in these cells. To investigate these pos‐
sibilities, we downregulated MX2 using two different MX2 target‐
ing siRNA oligos. A clear reduction in MX2 mRNA levels was seen 
after siRNA transfection without effecting MX1 (Figure S4a,b). 
Interestingly,	72	hr	post‐transfection,	a	significant	viability	decrease	
was seen in high MX2 expressing WM115 and MM382 cells, while 
subtle or no effects were seen in low MX2 expressing WM1366 cells 
(Figure 4a). To identify whether the observed decrease in viability 
was due to decreased proliferation or apoptosis, we examined the 
expression of mitosis marker phospho‐Histone H3 (pHH3) and the 
F I G U R E  3   MX2 overexpression inhibits melanoma cell growth both in vitro and in vivo.	(a)	Immunoblot	analysis	of	MX2	protein	
expression	in	normal	human	melanocytes	and	melanoma	cells	after	lentiviral	transduction.	Tet‐On	system	was	used	to	achieve	doxycycline‐
inducible	expression	of	MX2	and	GFP	in	normal	human	melanocytes.	Increased	MX2	protein	expression	seen	in	melanocytes	after	
administration of 500 ng/ml doxycycline for 48 hr and stable expression in melanoma lines. (b) Growth curves of cells overexpressing GFP 
or	MX2	were	obtained	using	IncuCyte	Zoom	live‐cell	imaging	system.	Curves	represent	fold	increase	of	cell	growth	versus	time	at	3‐hr	
intervals. Results are expressed as mean ± SE of three independent experiments. Wilcoxon matched‐pairs signed‐rank test was used for 
comparison between the groups. Statistically significant results are marked with asterisk, *** p	<	.001.	(c)	Image	of	harvested	tumors	at	
day 50 post‐subcutaneous injection of 2 × 106 WM983b cells stably expressing GFP or MX2. (d) Tumor volume at day 50 after injection. 
t test was applied to assess significance. (e) Assessment of AKT pathway activity by immunoblotting in lysates of the xenograft tumors 
overexpressing MX2 or GFP
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apoptotic marker‐cleaved caspase 3. As seen in Figure 4b, no nota‐
ble increase in caspase 3 cleavage was observed in any of the cell 
lines following MX2 downregulation, while a clear reduction in phos‐
phorylation of HH3 at serine 10 was evident in WM115 and MM382 
suggesting cell cycle‐related effect in these lines. The activation of 
the AKT and MAPK signaling pathways was also examined, but sur‐
prisingly no significant changes were observed (Figure S5).
Effects of MX2 downregulation on the cell cycle distribution 
were assessed by flow cytometry 48 hr post‐siRNA transfections. 
The analysis revealed that MX2 knockdown increased the propor‐
tion of cells in G1 phase, including weak effect in WM1366 sug‐
gesting induction of the cell cycle arrest (Figure 4c). As expected, 
G1 arrest was accompanied with decreased levels of cyclin D1 and 
kinase Cdk2 expression and increased levels of Cdk inhibitory pro‐
teins p27Kip1 and p21Cip1 (Figure 4d). Again, observed effects were 
more prominent in WM115 and MM382 cell lines than in WM1366.
Due to these notable effects on the cell cycle, we investigated 
whether MX2 expression itself could be oscillating during the cycle. 
Synchronization	of	the	cells	at	G1/S	boundary	by	double	thymidine	
block showed expected oscillation of the cyclins and mitotic phos‐
pho‐Histone H3 after release. MX2 levels, however, did not change 
during the cell cycle progression suggesting that its expression is cell 
cycle phase‐independent (Figure 4f).
To further investigate which cellular processes are influenced by 
MX2 downregulation, we also performed RNA‐seq of MM382 cells 
48 hr after siRNA transfection. A core of 520 differentially expressed 
genes (Table S3) overlapping between two siRNA oligos was selected 
for	further	GO	enrichment	analysis	(Figure	5a),	while	fifty	most	up‐	
and downregulated genes are presented in Figure 5b. The analysis 
showed	that	highly	over‐represented	GO	terms	included	processes	
involved in cell cycle regulation and progression (Figure 5c). Among 
significantly downregulated genes after MX2 downregulation was 
a major mitotic protein kinase Aurora A. The validation of RNA‐seq 
data by Western blot indeed confirmed that in WM115 and MM382 
lines Aurora A and its downstream target PLK1, which control cen‐
trosome maturation and spindle assembly at G2/M transition, are 
downregulated following MX2 siRNA transfection (Figure 5d). As a 
result, protein levels of downstream members of Aurora A—PLK1 
F I G U R E  4   MX2 downregulation perturbs cell cycle and reduces proliferation in a subset of melanoma lines. (a) Trypan Blue dye exclusion 
viability test 72 hr post‐transfection with two independent siRNAs for MX2 (#1 siMX2 and #2 siMX2) and negative control (siCTR). Viability 
counts	are	normalized	to	negative	control.	Results	are	expressed	as	mean	±	SE	of	three	independent	experiments.	Two‐tailed	paired	t 
test was used to test statistical significance. * p	<	.05.	(b)	Immunoblot	analysis	of	affected	apoptosis	and	proliferation‐associated	proteins	
upon MX2 knockdown. GAPDH was used as a loading control. (c) Evaluation of cell cycle distribution by flow cytometry using propidium 
iodide staining. Cells were transfected with #1 siMX2, #2 siMX2, and siCTR 48 hr prior to flow cytometric analysis. Bar graphs represent 
percentages	of	cells	in	different	cell	cycle	phases	(average	from	three	independent	experiments	±	SE).	(d)	Immunoblot	analysis	of	proteins	
involved	in	G1/S	transition	of	the	cell	cycle.	(e)	Oscillation	of	MX2	protein	level	during	cell	cycle	was	examined	by	releasing	MM382	cells	
synchronized	in	G1/S	phase	from	double	thymidine	block
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axis, including cdc25c and cyclin B1, were also reduced leading to 
impeded progression through G2/M. Jointly, our data suggest that 
even if MX2 is downregulated in metastatic samples and displays 
tumor‐suppressive function in the majority of melanoma lines, in a 
subset of melanomas, it displays proto‐oncogenic features and is an 
important factor necessary for cell cycle regulation and proliferation 
of these cells.
4  | DISCUSSION
In	 recent	 years,	 several	 GWAS	 have	 identified	 novel	 melanoma	
susceptibility SNPs, including in the intron of MX2 gene that have 
no previously defined functional roles in cancer‐related processes. 
Thus, the overall objective of our study was to investigate whether 
and how MX2 function can influence melanoma tumorigenesis. So 
far, MX2 has been mainly defined by its antiviral functions, high‐
lighting	its	induction	by	type	I	IFN	and	ability	to	interfere	with	the	
replication of different types of negative‐stranded RNA viruses. 
Our	expression	data	from	melanocytes,	and	primary	and	metastatic	
melanoma show that MX2 can be constitutively expressed indepen‐
dently	 of	 IFN	 induction,	which	 is	 in	 agreement	with	 two	previous	
studies in HeLa and T98G cells (King et al., 2004; Melén et al., 1996).
While we detected MX2 expression in all melanocyte and pri‐
mary melanoma cell lines, 8 out of 10 metastatic cell lines showed 
lower or lack of expression. There was also an apparent reduction 
of expression in a metastatic versus primary cell line derived from 
the same patient suggesting that MX2 is downregulated during 
disease progression. Furthermore, an increasing percentage of 
MX2	 IHC	 negative	 samples	 was	 observed	 in	metastatic	 lesions.	
The exact mechanism of this downregulation needs further elu‐
cidation,	but	 inactivation	of	the	IFN	pathway	and	suppression	of	
its target genes during disease development has been reported 
in melanoma as well as in other cancers (Katlinskaya et al., 2016; 
Katlinski	 et	 al.,	 2017;	Walter	 et	 al.,	 2017).	 Interestingly,	 a	 study	
of breast cancer by Han et al. (Han, Russo, Kohwi, & Kohwi‐
Shigematsu, 2008) found that transcription factor and chromatin 
organizer	 SATB1	 reprograms	 gene	 expression	 profile	 of	 cancer	
cells to promote tumor growth and that MX2 is among the re‐
pressed genes.
Here, we also showed that reintroduction of MX2 expression 
in endogenously low expressing cell lines leads to downregulation 
of AKT activity and inhibition of tumor growth in vitro and in vivo. 
These effects were profound in a metastatic WM983b suggesting 
that downregulation of MX2 is important during disease progres‐
sion.	Since	it	 is	demonstrated	that	type	I	and	II	 IFNs	used	in	mela‐
noma treatment due to their antiproliferative effects can regulate 
AKT activity in a complex manner (Kaur, Sassano, Dolniak, et al., 
2008; Kaur, Sassano, Joseph, et al., 2008), one can speculate if some 
of these effects can partially be mediated by MX2.
F I G U R E  5   Gene expression analysis 
of MM382 melanoma cells after MX2 
siRNA transfection (a) Venn diagram of 
differentially expressed genes (DEGs) 
between #1 siMX2, #2 siMX2, and 
siCTR. Pink circle represents the number 
of genes with different expression 
levels between #1 siMX2 versus siCTR. 
Green circle represents the number of 
genes with different expression levels 
between #2 siMX2 versus siCTR. Blue 
circle represents the number of genes 
with different expression levels between 
#1 siMX2 and #2 siMX2 versus siCTR. 
(b) Heatmap of 25 most upregulated 
(green) and downregulated (red) genes. 
(c)	GO	enrichment	analysis	of	biological	
processes for the 520 differentially 
expressed genes overlapping between 
#1 siMX2 and #2 siMX2. (d) Validation 
of RNA‐seq transcriptome analysis by 
immunoblotting
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The analysis of transcriptomic data from the Leeds Melanoma 
Cohort of 703 tumors and TCGA metastases showed that high ex‐
pression of MX2 mRNA was associated with better prognosis. We 
did not observe similar effects of protein expression in our second 
validation	cohort,	which	might	be	due	to	much	smaller	sample	size.	It	
is difficult to exclude the possibility that a significant component of 
the MX2 gene expression signal in the Leeds Melanoma Cohort is de‐
rived	from	TILs	which	themselves	are	a	favorable	prognostic	marker	
in melanoma (Fu et al., 2019). The expression of MX2 in tumor cells 
did, however, correlate with the amount of immune cell infiltration im‐
plying	that	IFN	secretion	by	TILs	leads	to	induction	of	MX2 and other 
IFN‐dependent	genes	like	MX1.	Indeed,	we	did	observe	a	correlation	
between MX2 and MX1 expression in tumor samples. However, we 
did not see such correlation in our panel of cell lines, suggesting that 
even	though	IFNs	are	major	regulatory	factors	of	MX2,	there	are	also	
other mechanisms involved. For instance, a recent study by Punia et al. 
found that Engrailed‐2 (EN2) transcription factor secreted by prostate 
tumors can induce MX2 expression in stromal cells (Punia, Primon, 
Simpson, Pandha, & Morgan, 2019), and MX2 was a single gene show‐
ing a dose–response relationship to recombinant EN2 treatment.
Interestingly,	the	observation	that	MX2 expression is borderline 
protective even in the low immune subgroup combined with the fact 
that some tumors display high MX2 immunoreactivity while lacking 
TILs,	 argues	 for	 its	 immune‐independent	 functions.	 Jointly,	 these	
results support the hypothesis that MX2 has tumor‐suppressive fea‐
tures in melanoma.
Inheritance	 of	 the	 minor	 C	 allele	 rs45430	 SNP	 in	 the	 intron	
of MX2 was reported to be protective for melanoma and multiple 
primaries in the GWAS (Barrett et al., 2011; Gibbs et al., 2015). Here, 
we	found	that	the	homozygous	C	allele	is	associated	with	lower	ex‐
pression of MX2 in primary melanoma tumors, and a similar trend 
was seen in metastatic samples. Since we also report that higher ex‐
pression levels of MX2 are seen in thinner primaries with a lower mi‐
totic rate and better survival, these data seem somewhat difficult to 
explain. However, it is known that expression quantitative trait loci 
(eQTL) can display opposite directional effects in a tissue‐specific 
manner	(Mizuno	&	Okada,	2019).	Indeed,	minor	C	allele	is	associated	
with lower MX2 expression in whole blood, while the opposite is 
seen for sun‐exposed skin (Figure S6) (TheGTExConsortium, 2015). 
Currently, it is unclear what functional role MX2 plays in different 
immune cell types or how this relates to melanoma risk; therefore, 
further studies are warranted.
Interestingly,	we	have	observed	similar	discrepancies	previously	
for an inherited SNP in the PARP1 gene. The SNP was associated 
with higher PARP1 levels, increased risk of melanoma, and related 
to PARP1 induced	cell	proliferation	mediated	through	MITF	(Choi	et	
al., 2017). Yet, the same SNP was found to be associated with a lower 
risk of death from melanoma (Davies et al., 2014).
Remarkably, despite its growth inhibitory effects and down‐
regulation in metastatic cell lines, a subset of melanoma lines in 
our panel exhibited high endogenous MX2 expression. Knockdown 
of MX2 in these lines decreased proliferation and lead to pertur‐
bation of the cell cycle, which is inconsistent with observations 
from our overexpression experiments. However, MX2 belongs to 
dynamin‐like GTPase family proteins, which are also known to be 
involved in the regulation of cell cycle progression and it is likely 
that MX2 function is complex and cell type‐ and context‐depen‐
dent.	In	support	of	these	observations,	one	previous	study	has	re‐
ported that depletion of endogenous MX2 in cancer cells results in 
delayed progression through G1/S phase of the cell cycle (King et 
al., 2004). We have observed similar G1 arrest accompanied with 
cyclin D1 degradation and cyclin E upregulation in p21‐dependent 
manner	as	reported	(Sandor	et	al.,	2000).	In	addition,	our	RNA‐seq	
analysis revealed that MX2 is also involved in DNA replication and 
mitosis processes partially by regulation of Aurora A and PKL1. A 
study by Kane et al. (2013) investigating MX2 potency to inhibit 
HIV‐1	 showed	 that	 arresting	 the	 cell	 cycle	 in	 osteosarcoma	 and	
myelogenous leukemia cells increases MX2 viral inhibitory activ‐
ity. We can speculate that antiviral MX2 potency in non‐dividing 
cells increases when it does not engage in other cellular processes, 
including DNA replication and/or mitosis as suggested by our 
study. These results further support the hypothesis of a cellular 
type‐ and setting‐dependent MX2 function.
In	summary,	we	have	demonstrated	that	widely	accepted	antivi‐
ral MX2 gene has tumor‐suppressive features in melanoma, where 
it regulates the growth of tumor cells partially through negative 
modification of AKT activity, and it is downregulated during disease 
progression. However, its role seems to be complex and cell context‐
dependent since we found that in a subset of melanoma cell lines, it 
is highly expressed and necessary for cell cycle progression. Further 
elucidation of this dual mechanism of action is needed to understand 
its complex roles in tumorigenesis.
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